Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.05). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $15.5 million.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.